Literature DB >> 15698374

Biomaterials for use in frontal sinus obliteration.

Matthew D'Addario1, Richard H Haug, Reena M Talwar.   

Abstract

Although fractures of the frontal sinus are infrequent (2-15% of victims of facial trauma), because of their proximity to the brain and eyes, the consequences of their management may have a significant impact on the patient. For frontal sinus injuries that affect the nasofrontal ducts or posterior wall, obliteration is indicated. Although frontal sinus surgery has been documented since 1750, a consensus as to the best material for obliteration has not been achieved. The particular autogenous and alloplastic materials for use in frontal sinus obliteration will be the focus of this review, with particular attention paid to assessing their physical properties, advantages, disadvantages, and complications. While numerous new alloplastic materials show promise for frontal sinus obliteration, autogenous fat remains the most popular and most frequently used material with the longest history of use, and it is versatile and reliable.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15698374     DOI: 10.1615/jlongtermeffmedimplants.v14.i6.30

Source DB:  PubMed          Journal:  J Long Term Eff Med Implants        ISSN: 1050-6934


  3 in total

1.  Frontal sinus obliteration with iliac crest bone grafts. Review of 8 cases.

Authors:  Marcelo Monnazzi; Marisa Gabrielli; Valfrido Pereira-Filho; Eduardo Hochuli-Vieira; Henrique de Oliveira; Mario Gabrielli
Journal:  Craniomaxillofac Trauma Reconstr       Date:  2014-06-12

2.  Frontal Sinus Obliteration Utilizing Autogenous Abdominal Fat Graft.

Authors:  Abla Eledeissi; Mamdouh Ahmed; Emad Helmy
Journal:  Open Access Maced J Med Sci       Date:  2018-07-21

3.  A practical and economical method for frontal sinus reconstruction after frontal craniotomy: A single-center experience with 140 patients.

Authors:  Youwei Guo; Xianyong Fu; Wen Yin; Zhipeng Jiang; Yirui Kuang; Zhaoping Wu; Yudong Cao; Jun Tan; Xing-Jun Jiang
Journal:  Front Surg       Date:  2022-07-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.